[The use of placebos in phase III clinical trials in Brazil].

Abstract

In 2008, Brazil's Federal Council of Medicine [Conselho Federal de Medicina] (CFM)--regulatory and supervisory agency on the ethical practice of medicine--banned the participation of Brazilian doctors in studies using placebos for diseases with efficient and effective treatment. This position differs with the Helsinki Declaration, which allows the use of placebos in methodologically justified conditions. To ascertain whether the CMF's ethical regulation modified the use of placebos in phase III clinical trials in Brazil, characteristics of the records in ClinicalTrials.gov were researched in the periods from 2003 to 2007 and from 2009 to 2013. The conclusions reached were: a) the regulations issued by the CFM in 2008 were ineffective and the position adopted by the Helsinki Declaration prevails; b) there was significant sponsorship by the multinational pharmaceutical industry of trials with placebos; c) the research was predominantly on new drugs for chronic diseases, with little study done of the neglected diseases which are of great importance to Brazil.

• Authors: Gustavo Butzge Rubenich, Stephanie Tomasi Heck, Fernando Hellmann, Bruno Rodolfo Schlemper Junior
• Journal: Salud colectiva (Salud Colect) Vol. 11 Issue 1 Pg. 99-114 (Mar 2015) ISSN: 1851-8265 [Electronic] Argentina
• Vernacular Title: El uso de placebo en ensayos clínicos de fase III en Brasil.
• PMID: 25853833 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Placebos

Topics

• Brazil
• Clinical Trials, Phase III as Topic (economics, ethics, methods, statistics & numerical data)
• Drug Industry (ethics)
• Helsinki Declaration
• Humans
• Placebos
• Research Support as Topic (ethics)